Datopotamab deruxtecan + Durvalumab + Carboplatin + AZD2936 + MEDI5752 + AZD7789
Phase 1Active 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced or Metastatic NSCLC
Conditions
Advanced or Metastatic NSCLC
Trial Timeline
Feb 2, 2021 → Apr 30, 2026
NCT ID
NCT04612751About Datopotamab deruxtecan + Durvalumab + Carboplatin + AZD2936 + MEDI5752 + AZD7789
Datopotamab deruxtecan + Durvalumab + Carboplatin + AZD2936 + MEDI5752 + AZD7789 is a phase 1 stage product being developed by Daiichi Sankyo for Advanced or Metastatic NSCLC. The current trial status is active. This product is registered under clinical trial identifier NCT04612751. Target conditions include Advanced or Metastatic NSCLC.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04612751 | Phase 1 | Active |
Competing Products
20 competing products in Advanced or Metastatic NSCLC